Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against α-synuclein oligomers/protofibrils

Immunotherapy against alpha-synuclein (α-syn) is a promising novel treatment strategy for Parkinson's disease (PD) and related α-synucleinopathies. We have previously shown that systemic treatment with the monoclonal oligomer/protofibril-selective antibody mAb47 targeting cytotoxic α-syn leads...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekmark-Lewén, S., Aniszewska, A., Molisak, A., Gumucio, A., Lindström, V., Kahle, P.J., Nordström, E., Möller, C., Fälting, J., Lannfelt, L., Bergström, J., Ingelsson, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407822/
https://www.ncbi.nlm.nih.gov/pubmed/37559953
http://dx.doi.org/10.1016/j.nbas.2023.100086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407822/
https://www.ncbi.nlm.nih.gov/pubmed/37559953
http://dx.doi.org/10.1016/j.nbas.2023.100086

Ejemplares similares